Senzime AB, the Uppsala-based medical device maker behind the TetraGraph neuromuscular monitoring system, will release its third-quarter 2026 financial report on October 29 and follow it with a webcast presentation and a live analyst Q&A session the same day. The events give investors, analysts, and media direct access to company leadership and a public forum for questions about the quarter's results.
What's scheduled and when
The report itself will be published at 08:00 am CEST on October 29. CEO Philip Siberg will then present the results via a webcast available from 09:00 am CEST on Senzime's investor website. An hour later, at 10:00 am CEST, a live Q&A hosted by Gustaf Meyer, an analyst at Redeye, will air through Redeye's platform. A recording of that session will be posted later the same day on Redeye's website for those unable to watch live.
How to participate
Anyone wishing to submit questions ahead of the Q&A can email Gustaf Meyer at Redeye directly, with a stated deadline of 10:00 am CEST on October 29 - the same time the session begins, so early submission is advisable for questions to be considered. Both the webcast and the recorded Q&A are intended to be publicly accessible, a format increasingly common among small- and mid-cap companies seeking to broaden engagement beyond traditional institutional analyst calls.
Company context
Senzime, founded in 1999, develops precision monitoring systems used in operating rooms to track neuromuscular transmission during surgery, aiming to support safer dosing of paralytic drugs and better-informed anesthesia care. Its flagship TetraGraph system is used in thousands of operating rooms worldwide. The company is listed on Nasdaq Stockholm's Main Market under the ticker SEZI and also trades over-the-counter in the United States under the symbol SNZZF, giving US-based investors a route to follow the Swedish company's quarterly disclosures alongside European shareholders.
What this means for stakeholders
For investors and analysts, the scheduled webcast and Q&A function as standard elements of quarterly reporting transparency rather than a novel announcement in themselves. The practical value lies in direct access to management commentary and the opportunity to pose questions in a public setting, which can help clarify figures in the report that are not otherwise explained in the written release. No financial results, guidance, or performance figures have been disclosed yet; those will only become available once the report is published on the morning of October 29.